London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Morning SOG, many thanks for that too, like I said earlier I just find it a bit weird. We are all eagerly awaiting news, the 2 patents are huge news and would give us a boost but no RNS. Yes the market will find out eventually, but with no RNS how? I guess they don't have time to research like you guys. Interesting times GLA
Morning again SOG. The patent that was posted re the crystalline compound had a tab on it which showed areas of protection. I mentioned that it had two sections, firstly global in which it listed I believe most of the world including China and then regards the US it had I believe all the states in alphabetical order.
So I believe we have everywhere between the North and south Pole covered. Atleast that's what I took from it.
Anyways off out now. All best steady.
Morning SOG.
All sounding positive. Have a great day.
Good morning Steadydanny.
Submarine patents,
Looking from info below. Our patent looks to be protected for 20 years from application date. Are sareum looking to get patent protection 'crystalline formulation of a compound' outside of the US?
Prior to changes in US patent law in 1995 and 1999, the content of patent applications was kept secret during the patent approval phase. Currently, the majority of U.S. patent applications are published within 18 months of the filing date (35 U.S.C. 122). However, the applicant can explicitly certify that they do not intend to file a corresponding patent outside the U.S. at the time they file the patent, and keep the application secret. The applicant can change their mind within the first year, but the application is then published. For continuation applications which claim priority to a previously filed application, the publication is six months after the new filing date. The changes to U.S. patent law that introduced publication at 18 months also changed the duration of the patent to 20 years from the filing date of the earliest patent application in any chain of continuation patent applications. As a result, there is little benefit in postponing the grant of the patent. The enforceable life of the patent can no longer be shifted into the period when a technology has become more widely adopted, and the patent applicant must give up the chance of foreign patent protection if he is to maintain patent secrecy beyond the 18-month period. In a 2006 report the National Academy of Sciences has recommended that "in all cases, applications should be published during patent examinations"
It would appear we are covered up to Oct 2040. (US only at the moment of course) would expect patent application now outside US.
Regards
Good morning Steadydanny.
Submarine patents,
Looking from info below. Our patent looks to be protected for 20 years from application date. Are sareum looking to get patent protection 'crystalline formulation of a compound' outside of the US?
Prior to changes in US patent law in 1995 and 1999, the content of patent applications was kept secret during the patent approval phase. Currently, the majority of U.S. patent applications are published within 18 months of the filing date (35 U.S.C. 122). However, the applicant can explicitly certify that they do not intend to file a corresponding patent outside the U.S. at the time they file the patent, and keep the application secret. The applicant can change their mind within the first year, but the application is then published. For continuation applications which claim priority to a previously filed application, the publication is six months after the new filing date. The changes to U.S. patent law that introduced publication at 18 months also changed the duration of the patent to 20 years from the filing date of the earliest patent application in any chain of continuation patent applications. As a result, there is little benefit in postponing the grant of the patent. The enforceable life of the patent can no longer be shifted into the period when a technology has become more widely adopted, and the patent applicant must give up the chance of foreign patent protection if he is to maintain patent secrecy beyond the 18-month period. In a 2006 report the National Academy of Sciences has recommended that "in all cases, applications should be published during patent examinations"
It would appear we are covered up to Oct 2040. (US only at the moment of course) would expect patent application now outside US.
Regards
Steady, believe me there are many of us who are absolutely elated that Tyk2 is getting so much patent coverage.
It is massive massive validation that it is something exceptionally unique or Dr Mitchell says differentiated and will take the pharma industry by storm.
It is no co-incidence that all this is newsflow and price movement is following the HNWI's investments and why they have demanded not to be named.
We are well and truly set for a re-rate and it is going to be very substantial as we expect- you would be worth £20m+ and invest in a small bio on AIM without doing some proper sit down and meet the BOD research. They'll get the 30-50bags and so will we.
Afham ... Hunting or iradication? I've heard they've all got myxomatosis so no use for testing purposes
On excellent form this evening Sad, thank you very much for the time you've taken out.
Oh and we should all go for a visit to the common to hunt some specimens for tox testing.
Cheers Mafuta. I did drop a hint re qbt as I like the majority of posters here and saw the Novacyt shenanigans before take off. It's about finding a company that is focused and has future scope. Which imo have a similar platform to the progress in mc increase here.
And ... The market will catch up ... Eventually
Danny enjoy your walk it will do you good ... I'm wandering in the Cotswolds with my grandbabies tomorrow ... Take care ... Mafuta
When the market wakes up..this from our board...note the 1802 x2 grant response but the additional relatively sublime comment which has yet to be RNSd!!
Additionally, a patent application describing a number of crystalline forms of a TYK2 inhibitor for medicinal applications, filed by Sareum in April 2020, was published on 14 October 2021. This type of patent is standard pharmaceutical industry practice and an important step to fully protect the intellectual property surrounding the Company's research programmes and to extend the life span of its patent portfolio.
I'm going to bed. Early coastal walk. Sincerely can't believe this is not a major discussion here.
In the wash ...
Yep steady this is something really big ... It will all come out in the was despite the trolls ... They are just an irritating diversion
Mafuta this
Intellectual Property
The Company had two new US patents granted during 2021 (in January and September) that reinforce the patent protection for SDC-1802 and its use in treating certain cancers (including pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma) by inhibiting TYK2 kinase.
Additionally, a patent application describing a number of crystalline forms of a TYK2 inhibitor for medicinal applications, filed by Sareum in April 2020, was published on 14 October 2021. This type of patent is standard pharmaceutical industry practice and an important step to fully protect the intellectual property surrounding the Company's research programmes and to extend the life span of its patent portfolio.
17 years? Submarine? Why have we had trolls?
Best wishes to sareum holders.
Yes steady ... There's a lot of intrigue around this patent ... But even if it's on a need to know basis it's still worthwhile asking the bod for more details ... Even if we just get an embarrassed cough and "we cannot comment on that at the moment" it will still be worthwhile asking
Food for thought SD.
Hi Mafuta
This
• Two new US patents granted (January and September 2021) strengthening patent protection, which is now in place across all major territories
Sounds like the submarine patent
And then
The patent (US 11,154,539) will grant on 26 October 2021 and will protect the SDC-1802 molecule and pharmaceutical preparations thereof as a therapeutic to treat cancer selected from pancreatic, colorectal and kidney cancers, melanoma, and B-cell lymphoma by inhibiting TYK2 kinase. This programme is in preclinical development.
And a post of mine earlier
Therefore, when the patent examiner “allows” your patent application, you do not let it “grant.” That would start your 17-year term. Rather, you file a “continuation” to keep it “underwater” or “pending.” During this time, competitors develop and adopt the technology. Once the industry embraces the technology, you finally allow your submarine patent to “surface.” This starts your 17-year patent term. However, now the technology is ubiquitous and you have greater leverage to force a settlement or payout.
So it's not necessarily about it being granted! It's a submarine patent!! So a continuation or pending can be reported in a RNS.
I doubt an epistolary RNS will be as per usual between the board and investors. I expect more than that.
I don't think we have officially accepted the grant, hence no RNS yesterday.
Steady there is nothing wrong with throwing a soft curve ball from time to time just to watch the body language ...
Sad we well may get that RNS in the next few days ... I don't believe they are sitting on the news as there is no advantage in doing so ... they cannot sit on regulatory news as they would get their behinds well and truly whacked by the exchange and regulators if they did ... I find the rash of wombles of late quite interesting ... we've seen it before just before news lands ... it's funny how they suddenly evaporate ... all part of the game I guess ...
EXAMPLE 7
Pharmaceutical Formulations
(i) Tablet Formulation
A tablet composition containing a crystalline form of the compound of the formula (1) as defined herein is prepared by mixing 50mg of the compound with 197mg of lactose (BP) as diluent, and 3mg magnesium stearate as a lubricant and compressing to form a tablet in a known manner.
(ii) Capsule Formulation
A capsule formulation is prepared by mixing 100mg of a crystalline form of the compound of the formula (1) as defined herein with 100mg lactose and filling the resulting mixture into standard opaque hard gelatin capsules.
(iii) Sub-cutaneous Injection Formulation
A composition for sub-cutaneous administration is prepared by mixing a crystalline form of the compound of the formula (1) as defined herein with pharmaceutical grade corn oil to give a concentration of 5mg/ml_. The composition is sterilised and filled into a suitable container.
Equivalents
The foregoing examples are presented for the purpose of illustrating the invention and should not be construed as imposing any limitation on the scope of the invention. It will readily be apparent that numerous modifications and alterations may be made to the specific embodiments of the invention described above and illustrated in the examples without departing from the principles underlying the invention. All such modifications and alterations are intended to be embraced by this application.
Good evening SD. Was rather expecting an RNS to state the successful granting of the patent.
A history of disruption here when good news is due. Sinister forces at work at certain times me thinks. Fairly substantial sized buys occur too.
Regards
labman you can have a butchers at below. Re crystallisation of Tyk2 compounds
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=58455E84F9A214ABBA3C53AD9AE0BB9A.wapp1nA?docId=WO2021204762&tab=PCTDESCRIPTION
Regards
Evening SOG. Re 1802
My thoughts on the Q and A is that they will only respond to official responses via RNSs reported. So the submarine patent is able to be ignored if a question arises.
That's why as I mentioned 2 days ago is that the updated 1802 patent would officially 'grant' yesterday. But our TU seemed to skip it on the 25th and just state it was granted as per September RNS. Which technically is not correct.it was purely set for approval which would be granted yesterday. Of which we have had no official update. That's where I scratch my head.
It's as if official reporting on 1802 is being stalled for some purpose.
Am I overthinking?
Just seems the recent negative/disruptive posts with no tangible substance to substantiate their posts are as apparent as around the Edison report and a month later the first HNWI Subscription. We all remember senator and sly...have we seen those names since....or are they incognito with similar negative posting techniques?
Many thanks for that.